Antidepressant decision aid for major depressive disorder patients (ADAM): Development and pilot testing

• Main Authors: Abousheishaa, Aya Ahmed, Mat Lazim, Nor Hazila, Tang, Song Ling, Sulaiman, Ahmad Hatim, Zaman Huri, Hasniza, Guan, Ng Chong
• Format: Article
• Published: Elsevier 2022
• Subjects: RS Pharmacy and materia medica
• Online Access: http://eprints.um.edu.my/41927/

Objectives: This study aimed to develop and assess the effectiveness of an encounter decision aid for Malaysian patients with MDD to support treatment decision-making during the consultation.Methods: The decision aid prototype was developed following a literature review and six focus groups. Alpha testing assessed its comprehensibility, acceptability, usability and desirability through user-centered cognitive interviews. Beta-testing evaluated preliminary evidence on its efficacy using the SDM Scale and PDMS. Feasibility was assessed by timing the consultation.Results: The alpha testing demonstrated that the decision aid was patient-oriented, comprehensible, comprehensive, concise and objective with an appealing design. Beta-testing indicated that PtDA significantly increased patients satisfaction with SDM from patients' 83.32 (13.92) vs 85.76 (13.80); p < 0.05] and physicians' 81.07 (10.09) vs 86.36 (10.10); p < 0.05] perspectives and prepared the patients for decision making from the patients' PDMS patients: 84.10 (12.69)] and physicians' PDMS physicians: 83.78 (16.62)] perspectives as well. There was no change in the consultation time between the control and the intervention groups.Conclusions: We developed an antidepressant PtDA for Malaysian patients with MDD that increases patients' involvement in shared decision making and enhances their preparedness for decision making. Practice implications: Using the PtDA can support collaborative decision-making in routine clinical practice without extending the consultation time.(c) 2021 Elsevier B.V. All rights reserved.